- ADVERTISEMENT
-
Most Popular
- ADVERTISEMENT
VRX
Is Valeant Pharmaceuticals Intl Inc a Buy? 3 Pros, 3 Cons
Under CEO Joseph Papa, Valeant has reduced its debt by over $6 billion. But legal liabilities for the company remain. Is VRX stock a buy?
Valeant Pharmaceuticals Intl Inc Stock Is Worth the Risk
Valeant stock looks poised for recovery as a new CEO is turning VRX around by paying off debts and creating new markets for Valeant products.
Earnings Momentum Keep Valeant Pharmaceuticals International (VRX) a Buy
Valeant Pharmaceuticals International Inc (NYSE:VRX) ranks in the top 25% of its industry group, Pharmaceuticals, and in the top 25% of its sector group, Health Care, with a market value of $7.2 billion. From an investment attractiveness viewpoint, VRX is ranked in the top quartile of the sector with a ranking of 148 among the 779 companies in the sector; the stock's Portfolio Grader ranking places it 21 among the 134 companies in this industry group, giving it a well above-average position and number 871 in the 5000 company Portfolio Grader company universe.
Valeant Pharmaceuticals International (VRX) a Buy on Solid Earnings Visibility
Valeant Pharmaceuticals International Inc (NYSE:VRX) ranks in the top 25% of its industry group, Pharmaceuticals, and in the top 25% of its sector group, Health Care, with a market value of $7.2 billion. From an investment attractiveness viewpoint, VRX is ranked in the top quartile of the sector with a ranking of 148 among the 779 companies in the sector; Portfolio Grader's current ranking for VRX puts it 21 among the 134 companies in this industry group, giving it a well above-average position and number 871 in the 5000 company Portfolio Grader company universe.
Valeant Pharmaceuticals International (VRX) a Buy on Healthy Earnings Visibility
Portfolio Grader currently ranks Valeant Pharmaceuticals International Inc (NYSE:VRX) a Buy. Using Louis Navellier's investing methodology, this analytical tool assesses stocks by means of fundamental and quantitative metrics. VRX has maintained this ranking for the last month.
Be Extremely Careful With Valeant Pharmaceuticals Intl Inc Stock Price
The VRX stock price has surged, but the move isn't that big when accounting for the company's debt -- debt that could turn into an anchor.
Valeant Pharmaceuticals Intl Inc Has Turnaround in Store
VRX stock is still apt to be hot and cold going forward, but it's a "more hot than cold" scenario that suggests Valeant Pharmaceuticals has better days ahead.
Stocks Skittish on Tax Worries
Stocks fell on amid doubts over the fate of the GOP's tax cut plans. The doubt hit investors after a number of Republican senators expressed reservations about the amount of the child tax credit.
Tuesday’s Vital Data: Tesla Inc (TSLA), Apple Inc. (AAPL) and Valeant Pharmaceuticals International, Inc. (VRX)
Tesla (TSLA) Model 3s at distribution centers, Apple (AAPL) options rise on Shazam and Valeant launches Vyzulta, eyes FDA on Luminesse.
Despite Valeant Improvement, VRX Stock Price Is Still Too High
Give Valeant credit for its performance so far in 2017, but even at $14/share that progress appears to be factored in to the VRX stock price.
Valeant Pharmaceuticals Intl Inc: On the Long Path Unwinding
Valeant has paid back $5 billion in debt, but still owes $26 billion on sales of $8 billion. So, investors in VRX stock should be cautious.
Valeant Pharmaceuticals Intl Inc Is Looking Healthy
After Valeant beat expectations, VRX stock soared 17%. The rally is not yet over as the turnaround unfolds.
Valeant Pharmaceuticals Intl Inc Rockets Higher on a Robust Q3
Valeant Pharmaceuticals (VRX) stock was taking off on Tuesday with a strong earnings report for the third quarter of the year.
Tuesday’s Vital Data: Alibaba Group Holding Ltd (BABA), Teva Pharmaceutical Industries Ltd (ADR) (TEVA) and Valeant Pharmaceuticals Intl Inc (VRX)
Alibaba (BABA) options jump on target hike, Teva (TEVA) put options pile despite billionaire stake interest and Valeant (VRX) divests Sprout.
Brace Yourself When Valeant (VRX) Reports Earnings
Valeant's (VRX) stock is falling ahead of its earnings report. Its prospects are far from certain but management is making the right moves.
Here’s What to Expect With Valeant Pharmaceuticals Intl Inc Q3 Results
Valeant's pared debt and sold assets. Even a small earnings beat or stronger outlook next month could send VRX stock sharply higher.
The Lesson of Enterprise Value for Valeant Pharmaceuticals Intl Inc
Despite some promising new products, when considering Valeant's debt and equity value, VRX stock is not worth your investment.
3 Reasons to Stay Away From Valeant Pharmaceuticals Intl Inc Stock
Valeant has pulled off a nice rally, but with high debt and a weak pipeline, investors in VRX stock should still be wary.
Buy More Shopify Inc (US) While It’s Down
There’s no price guarantee with Shopify, but a solid correction builds the case for a well-placed and limited-risk SHOP bull call spread.
